<DOC>
	<DOC>NCT01666743</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of ceftaroline fosamil in elderly subjects with community-acquired bacterial pneumonia (CABP) receiving antibiotic therapy in the hospital.</brief_summary>
	<brief_title>Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia</brief_title>
	<detailed_description>This is a multicenter study of ceftaroline fosamil in elderly subjects (≥ 65 years of age) with CABP. Adjunctive macrolide therapy is to be used at the Investigator's discretion. A switch to oral treatment may be allowed at the discretion of the Investigator. The total duration of therapy is 5 to 7 days; a minimum of 48 hours of study drug is required.</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>1. Male or female ≥ 65 years of age. 2. Presence of CABP warranting hospitalization. 3. Acute illness with ≥ 2 clinical signs or symptoms of lower respiratory tract infection. 4. Radiographically confirmed pneumonia. 1. History of any hypersensitivity or allergic reaction to any βlactam or macrolide antibacterial agent. 2. Confirmed or suspected respiratory tract infection due solely to an atypical bacterial, mycobacterial, viral, or fungal pathogen. 3. More than 24 hours of potentially effective antibacterial therapy within 96 hours prior to enrollment. 4. Life expectancy of &lt; 30 days or presence of an order of Do Not Resuscitate (DNR). 5. Evidence of significant hematologic, hepatic, or immunologic impairment.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Community-Acquired Pneumonia</keyword>
	<keyword>Lung</keyword>
	<keyword>Adult</keyword>
	<keyword>Infections</keyword>
</DOC>